Phaseline

Companies › Tolmar

Tolmar: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 4, 1 Phase 2; Oncology, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Testosterone Undecanoate
Androgen Receptor agonist
ARPhase 4Hypogonadism; Prostate Cancer–
TOL2506
GnRH receptor agonist for ovarian suppression
GNRH1Phase 3Breast CancerJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06385509Testosterone UndecanoatePhase 4HypogonadismMetabolic and endocrineNov 2025
NCT05081193Testosterone UndecanoatePhase 2Prostate CancerOncologyDec 2026
NCT04906395TOL2506Phase 3Breast CancerOncologyJan 2027

Targets

GNRH1 (1) AR (1)

Companies with the same targets

Johnson & Johnson (Janssen) Novartis Astellas Alessa Therapeutics Sun Pharmaceutical Industries Debiopharm International Hansoh BioMedical R&D Company Merck & Co. (MSD) Bayer Qilu Pharmaceutical

Companies built like this

Aragon Pharmaceuticals Acrotech Biopharma LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.